Document:

CONFIDENTIAL TREATMENT REQUESTED                                    EXHIBIT 10.8

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24(B)(2) OF THE SECURITIES AND
EXCHANGE ACT OF 1934. CONFIDENTIAL TREATMENT REQUESTED IS REQUESTED AND IS NOTED
WITH "[CONFIDENTIAL TREATMENT REQUESTED]." AN UNREDACTED VERSION OF THIS
DOCUMENT HAS BEEN PREVIOUSLY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

                        AMENDMENT TO PATENT AND KNOW-HOW
                             ASSIGNMENT AND LICENSE
                                OPTION AGREEMENT
                                  BY AND AMONG
                             THE SCHOOL OF PHARMACY,
                              UNIVERSITY OF LONDON
                                       AND
                              SOMANTA INCORPORATED
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                                    The School of Pharmacy,
                                                    University of London
                                                    29-39 Brunswick Square,
                                                    London WC1N 1AX
Somanta Incorporated
80 Harley Street
London W1G 7HL England                                    21st September 2005

Dear Aga,

         Re:      Prodrax patent [CONFIDENTIAL TREATMENT REQUESTED]

The School of Pharmacy, as owner of the "Prodrax patent" as described above,
wishes to assign the rights in this patent to Somanta. As discussed in our
meeting on Friday 16th September, assignment is made on the basis of the terms
outlined in the "Patent and know-how assignment and license option agreement"
dated 16th March 2004 between the School of Pharmacy and Somantis Limited. In
addition, Somanta agrees to the following:

         o        Assignment of the patent back to the School of Pharmacy should
                  the proposed merger and subsequent financing of Somanta fail
                  to occur. Somanta hereby agrees to re-assignment of the
                  Prodrax patent to the School of Pharmacy in the case that
                  Somanta fails to raise a minimum of $10 million by December
                  31, 2005.

         o        That the lead inventor, Professor Laurence Patterson, and/or
                  researchers at the School of Pharmacy retain rights to perform
                  non-commercial research using the invention described in the
                  patent and to publish the results thereof;

         o        That Somanta will use its best efforts to reach a research and
                  development agreement with the lead inventor to progress the
                  invention;

         o        Payment of a [CONFIDENTIAL TREATMENT REQUESTED] royalty on Net
                  Sales (as described below) of any product covered by the
                  Prodrax patent worldwide.

Definition of Net Sales
-----------------------

For product incorporating the invention covered by the Prodrax patent sold by
Somanta, its inheritors in title, or a Sub-license Net Sales shall mean the
amounts actually collected for sales of products to a Third Party trade
purchaser (the "Customer") by Somanta or its Affiliates, less the following
items to the extent they are paid or allowed and included in the invoice price:

(i)      quantity, trade and/or cash discounts actually granted;

(ii)     amounts repaid or credited and allowances including cash, credit or
free goods allowances, given by reason of charge-backs, retroactive price or
billing errors and rebates (including government-mandated rebates);

(iii)    amounts refunded or credited for Products which were rejected or
damaged;

                                       2
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

(iv)     freight, shipment and insurance costs incurred in transporting Products
to Customers; and

(v)      taxes, tariffs, customers duties and surcharges and other governmental
charges incurred in connection with the sale, exportation or importation of
Products.

Should a product be sold in a combination package containing therapeutically
active materials in addition to a product, "Net Sales", for the purpose of
determining payments due to the School of Pharmacy on a product within that
combination package, shall be calculated as follows:

Net Sales of combination package x A/(A+B)

Where:

"A" is the net selling price, during the period in question to which the
payments refers, of a product sold separately; and

"B" is the aggregate of the net selling prices, during the payment period in
question, of the other therapeutically active materials sold separately.

In the event that a product is sold in the form of a combination package
containing one or more therapeutically active materials in addition to a product
and one or more of those therapeutically active materials is not sold
separately, then the parties shall negotiate in good faith and agree on an
appropriate royalty adjustment to reflect the relative significance (based on
reasonable fair market value) of the Product compared to the other
pharmaceutically active material(s) in the combination package.

Please sign below by way of agreement to these terms of assignment, subject to
the approval of the Board of Directors of Somanta Incorporated, or its successor
and assigns.

The parties acknowledge and agree that the Research Collaboration Agreement
dated March 31, 2004 between the School of Pharmacy and Somanta Limited
(formerly Somantis Limited) has been previously terminated and is of no further
force or effect. In addition, the School of Pharmacy acknowledges and agrees
that the Patent and know-how assignment and license option agreement dated March
16, 2004 between the School of Pharmacy and Somanta Limited (the "Option
Agreement") has been assigned by Somanta Limited to Somanta Incorporated, a
Delaware corporation, in accordance with Section 9.3.2 of the Option Agreement.

Somanta Incorporated hereby undertakes to be bound by and perform the
obligations of Somanta Limited under the Option Agreement as supplemented by
this letter agreement.

                                       3
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

Signature:        illegible
          -----------------------------------

Date:    21/9/05
     ----------------------------------------

Yours faithfully,

/s/ BILL LINDSAY

Bill Lindsay
Business Development Manager, The School of Pharmacy

                                       4CONFIDENTIAL TREATMENT REQUESTED                                    EXHIBIT 10.9

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24(b)(2) OF THE SECURITIES AND
EXCHANGE ACT OF 1934. CONFIDENTIAL TREATMENT REQUESTED IS REQUESTED AND IS NOTED
WITH "[CONFIDENTIAL TREATMENT REQUESTED]." AN UNREDACTED VERSION OF THIS
DOCUMENT HAS BEEN PREVIOUSLY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

                             RESEARCH COLLABORATION
                                   AND LICENSE
                                    AGREEMENT
                                  BY AND AMONG
                      ADVANCED CARDIOVASCULAR DEVICES, INC.
                                       AND
                                 SOMANTA LIMITED
<PAGE>
                                              [CONFIDENTIAL TREATMENT REQUESTED]

                  RESEARCH COLLABORATION AND LICENCE AGREEMENT
                  --------------------------------------------

         This agreement dated August 1, 2004 is between:

         (1)      ADVANCED CARDIOVASCULAR DEVICES, INC. ("ACD"); a California
corporation with principal address at 26261 Glen Canyon, Laguna Hills, CA 92653.

         (2)      SOMANTIS LIMITED ("Somantis") a company incorporated in
England and Wales, (with company number 4201851) whose registered office is at
117 Alexandra Park Road, London N10 2DP.

         RECITALS:

         A.       Somantis is the owner of the Somantis Intellectual Property
(as defined below).

         B.       Somantis is willing to grant to ACD and ACD is willing to
accept, a license of the Somantis Intellectual Property (as defined below),
solely for use in the Field (as defined below).

         C.       ACD is willing to use the Somantis Intellectual Property to
carry out ACD's Project Responsibilities (as defined below) and for
commercialization of the resulting products.

         NOW THEREFORE, for good and valuable consideration, included the
premises and mutual promises herein, IT IS AGREED as follows:

1.       DEFINITIONS
         -----------

         In this agreement the following words shall have the following
meanings:

         1.1      "ACD's Project Responsibilities"      The work to be carried
                                                        out by ACD in connection
                                                        with the Research
                                                        Project, including the
                                                        creation of a drug
                                                        coated cardiovascular
                                                        device, carrying out

                                      -2-
<PAGE>
                                              [CONFIDENTIAL TREATMENT REQUESTED]

                                                        preclinical and clinical
                                                        research with the intent
                                                        to obtain regulatory
                                                        approval for the drug
                                                        coated cardiovascular
                                                        device, and if
                                                        successful in clinical
                                                        research, the
                                                        commercialization
                                                        thereof.

         1.2      "Background Information"              any information and/or
                                                        know-how made available
                                                        by either party to the
                                                        other party pursuant to
                                                        Clause 4.1.

         1.3      "Commencement Date"                   The Commencement Date
                                                        shall be the date of
                                                        signing of this
                                                        agreement.

         1.4      "Field"                               The treatment of
                                                        vascular disorders or
                                                        proliferation using
                                                        stents and devices.

         1.5      "Intellectual Property"               Trade marks, service
                                                        marks, trade names,
                                                        logos, Know-How,
                                                        patents, inventions,
                                                        rights in designs, trade
                                                        or business names,
                                                        copyrights and
                                                        topography rights
                                                        (whether or not any of
                                                        these is registered and
                                                        including applications
                                                        for registration of any
                                                        such thing) and rights
                                                        under licences and
                                                        consents in relation to
                                                        any such thing and all
                                                        rights or forms of
                                                        protection of a similar
                                                        nature or having
                                                        equivalent or similar

                                      -3-
<PAGE>
                                              [CONFIDENTIAL TREATMENT REQUESTED]

                                                        effect of these which
                                                        may subsist anywhere in
                                                        the world, and all
                                                        improvements thereto.

         1.6      "Know-how"                            Technical and other
                                                        information which is not
                                                        in the public domain
                                                        including information
                                                        comprising or relating
                                                        to concepts,
                                                        discoveries, data,
                                                        designs, formulae,
                                                        ideas, inventions,
                                                        methods, models, assays,
                                                        research plans,
                                                        procedures, designs for
                                                        experiments and tests
                                                        and results of
                                                        experimentation and
                                                        testing (including
                                                        results of research or
                                                        development), processes,
                                                        laboratory records,
                                                        chemical, toxicological,
                                                        clinical, analytical and
                                                        quality control data,
                                                        trial data, case report
                                                        forms, data analyses,
                                                        reports or summaries and
                                                        information contained in
                                                        submissions to and
                                                        information from
                                                        regulatory authorities.

         1.7      "Net Sales Value"                     The [CONFIDENTIAL
                                                        TREATMENT REQUESTED] of
                                                        Royalty-bearing Products
                                                        sold or in any way
                                                        transferred of like kind
                                                        by ACD or sub-licensees
                                                        or its Affiliates to
                                                        independent third
                                                        parties in arm's length
                                                        transaction, or, where

                                      -4-
<PAGE>
                                              [CONFIDENTIAL TREATMENT REQUESTED]

                                                        the Royalty-bearing
                                                        Products are sold in a
                                                        commercial transaction,
                                                        and this sale is not at
                                                        arm's length, the price
                                                        that would have been so
                                                        [CONFIDENTIAL TREATMENT
                                                        REQUESTED] if it had
                                                        been at arm's length,
                                                        after deduction of
                                                        normal trade discounts
                                                        actually granted and any
                                                        credits actually given
                                                        and, provided the
                                                        amounts are separately
                                                        charged on the relevant
                                                        [CONFIDENTIAL TREATMENT
                                                        REQUESTED], any costs of
                                                        packaging, insurance,
                                                        carriage and freight,
                                                        any value added tax or
                                                        other sales tax, and any
                                                        import duties or similar
                                                        applicable government
                                                        levies.

         1.8      "Project Intellectual Property"       All Intellectual
                                                        Property arising out of
                                                        the Research Project
                                                        including, without
                                                        limitation, the Project
                                                        Information.

         1.9      "Project Information"                 All discoveries,
                                                        inventions, results,
                                                        data, analyses, designs,
                                                        formulae, processes,
                                                        specifications, reports,
                                                        methods, know-how,
                                                        drawings or other
                                                        information arising out
                                                        of the Research Project.

                                      -5-
<PAGE>
                                              [CONFIDENTIAL TREATMENT REQUESTED]

         1.10     "Project Plan"                        The plan for the
                                                        Research Project
                                                        attached hereto as
                                                        Schedule I.

         "Research Project"                             The research project
                                                        described in Clause 2.

         1.11     "Research Team"                       The persons engaged in
                                                        the Research Project.

         1.12     "Somantis Intellectual Property"      All Intellectual
                                                        Property in the Field
                                                        owned by Somantis and
                                                        created during research
                                                        carried out by Somantis
                                                        (including without
                                                        limitation the Somantis
                                                        Patents and the Somantis
                                                        Know-How).

         1.13     "Somantis Know-How"                   All Know-How in the
                                                        Field owned by Somantis
                                                        and created during
                                                        research carried out by
                                                        Somantis.

         1.14     "Somantis Patents"                    All patents and patent
                                                        applications throughout
                                                        the world, including,
                                                        but not limited to U.S.
                                                        Patent application
                                                        number [CONFIDENTIAL
                                                        TREATMENT REQUESTED],
                                                        known as the Alchemix
                                                        patent, relating to a
                                                        series of substituted
                                                        anthraquinones including
                                                        any continuations,
                                                        continuations in part,
                                                        extensions, reissues,
                                                        divisions, and any
                                                        patents, supplementary
                                                        protection certificates

                                      -6-
<PAGE>
                                              [CONFIDENTIAL TREATMENT REQUESTED]

                                                        and similar rights that
                                                        are based on or derive
                                                        priority from the
                                                        foregoing, and all
                                                        improvements on
                                                        inventions in such
                                                        patents and patent
                                                        applications.

1.15     "Somantis' Project Responsibilities"           The work to be carried
                                                        out by Somantis in
                                                        connection with the
                                                        Research Project
                                                        including the production
                                                        and provision of small
                                                        amounts of Alchemix to
                                                        ACD at no cost through
                                                        phase two completion and
                                                        thereafter at cost for
                                                        research and development
                                                        purposes

2.       THE RESEARCH PROJECT
         --------------------

         2.1      ACD and Somantis shall use reasonable commercial efforts to
carry out their respective Project Responsibilities with reasonable skill and
care, and in accordance with the timetable set out in the Project Plan.

         2.2      At the end of each six month period commencing as of the
Commencement Date, ACD shall supply Somantis with a progress report on the
Research Project setting out following:

                  2.2.1   the work which ACD has carried out on the Research
                  Project during the previous 6 months .

                  2.2.2   any data and/or results obtained during the previous 6
                  months; and

                  2.2.3   the work that ACD intends to carry out during the next
                  6 months .

                                      -7-
<PAGE>
                                              [CONFIDENTIAL TREATMENT REQUESTED]

         2.3      Within 14 days of the end of each calendar quarter the parties
shall meet or have a conference call to discuss progress on the Research Project
in general and in particular ACD's latest progress report submitted under Clause
2.2.

3.       PAYMENT
         -------

         3.1      All sums due under this Agreement shall be paid in U.S.
Dollars.

         3.2      Sums specified in this Agreement are exclusive of Value Added
Tax or any similar tax which shall be the responsibility of Somantis.

         3.3      Funds will be raised within one year of signing this agreement
and within 30 days of raising the funds , ACD shall pay Somantis the
non-refundable, non-deductible sum of [CONFIDENTIAL TREATMENT REQUESTED].

         3.4      If ACD fails to meet the milestone dates as set forth in
clause 3.5.1 and 3.5.2, Somantis will have the right but not the obligation to
terminate this agreement (including the license granted hereunder), provided,
that ACD can eliminate this termination right by paying a missed milestone fees
as set forth below:

                  3.4.1 [CONFIDENTIAL TREATMENT REQUESTED] after the completion
                  of Phase I clinical study (as defined in Schedule I) but prior
                  to ACD initiating Phase II clinical trials.

                  3.4.2 [CONFIDENTIAL TREATMENT REQUESTED] after completion of
                  Phase II clinical trials.

                  3.4.3 [CONFIDENTIAL TREATMENT REQUESTED] after completion of
                  Phase III clinical trials.

                  3.4.4 [CONFIDENTIAL TREATMENT REQUESTED] after FDA approval
                  and prior to launch

                                      -8-
<PAGE>
                                              [CONFIDENTIAL TREATMENT REQUESTED]

         3.5      ACD will pay Somantis a royalty of [CONFIDENTIAL TREATMENT
REQUESTED] of Net Sales Value of ACD products covered by one or more claims of
the Somantis Patents and also by Project Intellectual Property, for sales in the
region covered only, marketed by ACD or by a third party on behalf of ACD. In
the event that ACD pays other royalties for other third party intellectual
property in relation to the Somantis Patents for such ACD products, ACD may
reduce the royalties payable to Somantis under this section in an amount equal
to the royalties payable to such third party, to a maximum reduction of
[CONFIDENTIAL TREATMENT REQUESTED].

4.       OWNERSHIP AND USE OF BACKGROUND INFORMATION AND THE PROJECT
         -----------------------------------------------------------
         INTELLECTUAL PROPERTY
         ---------------------

         4.1      Each party shall make available to the other party such
background information as may assist the parties in carrying out their
responsibilities under the Research Project, provided that nothing in this
Clause 4.1 shall oblige either party to act in breach of a confidentiality
obligation owed to any third party.

         4.2      Somantis will provide to ACD at no charge, reasonable
quantities of Alchemix, and any improvements thereto, as reasonably required by
ACD to complete the Research Project.

         4.3      If either party makes or acquires any Project Intellectual
Property it shall forthwith disclose the same in confidence to the other party.
Project Intellectual Property made or acquired by ACD shall remain the property
of ACD and Project Intellectual Property made or acquired by Somantis shall
remain the property of Somantis. Project Intellectual Property made or acquired
arising from work carried out jointly shall belong to the parties equally unless
they shall otherwise agree.

                                      -9-
<PAGE>
                                              [CONFIDENTIAL TREATMENT REQUESTED]

         4.4      Somantis grants to ACD a non-exclusive, royalty-free license
to make use of the Somantis Intellectual Property solely for the purposes of
carrying out ACD's Project Responsibilities under the Research Project.

         4.5      Somantis grants to ACD an exclusive, world-wide license of the
Somantis Intellectual Property, with rights to sublicense, to make, have made,
use, offer to sell, sell, import and export products for use in the Field.

         4.6      Without prejudice to the generality of Clauses 4.4 and 4.5,
Somantis shall have the exclusive right to apply for patents in respect of
inventions made by Somantis in the course of the Research Project, and ACD shall
provide Somantis with such assistance as Somantis shall from time to time
request in connection with the filing and prosecution of such patent
applications.

         4.7      ACD will have the exclusive right, but not the obligation, to
apply for patents in respect to inventions made by ACD, including inventions on
drug coated and coating devices, and Somantis will provide ACD with such
assistance ACD shall from time to time request in connection with the filing and
prosecution of such patent applications.

         4.8      Somantis represents and warrants that it has the right to
grant the rights granted herein to ACD, and that no other agreements or
commitment conflict with this Agreement.

5.       CONFIDENTIAL INFORMATION AND PUBLICATIONS
         -----------------------------------------

         5.1      In this Agreement, subject to Clause 5.2:

                  5.1.1    "Confidential Information" belonging to Somantis
         shall include Somantis's Background Information, the Somantis Know-How
         and any other information disclosed to ACD by Somantis relating to
         Somantis's business, technical and/or research plans;

                                      -10-
<PAGE>
                                              [CONFIDENTIAL TREATMENT REQUESTED]

                  5.1.2    "Confidential Information" belonging to ACD shall
         mean all Project Information and ACD's Background Information, and any
         other information disclosed to Somantis by ACD relating to ACD's
         business, technical and/or research plans.

         5.2      "Confidential Information" shall not include any information
which:

                  5.2.1 is or becomes public knowledge through no improper
conduct on the part of the party receiving the Confidential Information; and/or

                  5.2.2 is already lawfully possessed by the party receiving
Confidential Information prior to receiving it; and/or

                  5.2.3 is obtained subsequently from a third party without any
obligations of confidentiality and such third party is in lawful possession of
such material and is not in violation of any contractual or legal obligation to
maintain the confidentiality of such material.

         5.3      The onus shall be on the party asserting that any of the
exceptions set out in Clause 5.2 apply to prove that such exceptions apply.

         5.4      Each party shall, and shall procure that its respective
employees and members of the Research Team shall, keep confidential all
Confidential Information belonging to the other party and shall not use any
Confidential Information belonging to the other party other than for the
purposes of carrying out the Research Project and/or exercising its rights
hereunder.

         5.5      Each party shall take all reasonable steps to:

                  5.5.1    minimize the disclosure of Confidential Information
         belonging to the other party;

                  5.5.2    ensure that only the Research Team shall have access
         to Confidential Information belonging to the other party; and

                                      -11-
<PAGE>
                                              [CONFIDENTIAL TREATMENT REQUESTED]

                  5.5.3    ensure that its Research Team members use
         Confidential Information belonging to the other party for the sole
         purpose of carrying out the Research Project or exercising its rights
         hereunder.

         5.6      Each party shall procure that each of its employees and
members of the Research Team are bound by appropriate confidentiality and
non-use obligations in respect of Confidential Information belonging to the
other party.

         5.7      ACD shall be entitled to publish the results of work carried
out by ACD under the Research Project provided that:

                  5.7.1    ACD has first submitted to Somantis a complete copy
         of the proposed text of the publication (or an abstract which includes
         the results to be published) at least 30 days prior to prior to its
         disclosure to any third party; and

                  5.7.2    the proposed publication does not contain any
         Confidential Information belonging to Somantis.

         5.8      Any publication of the results of the Research Project shall
acknowledge the assistance of Somantis, to the extent such assistance was
rendered.

         5.9      The obligations of confidentiality and non-use set out in this
Clause 5 shall remain in force and shall be binding upon the parties for so long
as any party has knowledge or possession of any Confidential Information
belonging to the other party and for the avoidance of doubt shall survive any
termination or cancellation of this Agreement.

6.       DURATION AND TERMINATION
         ------------------------

         6.1      This Agreement shall commence on the Commencement Date and
shall expire on the last to expire of the Somantis Patents covering the ACD
Products unless sooner terminated in accordance with the provisions of this
Clause 6.

                                      -12-
<PAGE>
                                              [CONFIDENTIAL TREATMENT REQUESTED]

         6.2      Either party may terminate this Agreement forthwith if:

                  6.2.1    the other party breaches any provision of this
         Agreement and, having been notified of such breach, fails to remedy it
         within 30 days of notification; or

                  6.2.2    any of the following events occur:

                           6.2.2.1  an order is made or a resolution passed for
                  the winding up of the other party (other than for the purpose
                  of a solvent scheme of reconstruction or amalgamation);

                           6.2.2.2  an administration, administrative receiver
                  or receiver is appointed in respect of a material part of the
                  other party's assets or business; or

                           6.2.2.3  as a consequence of financial difficulties
                  the other party makes any voluntary arrangement with its
                  creditors; or

                           6.2.2.4  the other party ceases to continue its
                  business; or

                           6.2.2.5  the other party becomes unable to pay its
                  debts as and when they fall due;

                           6.2.2.6  as a consequence of debt and/or
                  maladministration, the other party takes or suffers any
                  similar or analogous action to those listed in Clauses 6.2.2.1
                  to 6.2.2.3 above.

         6.3      ACD may terminate this Agreement forthwith, without further
obligations to Somantis, if the technology licensed from Somantis does not
perform to the reasonable satisfaction of ACD, or cannot reasonably be
commercialized because of safety or efficacy reasons, or because ACD is unable
to raise appropriate funds.

7.       CONSEQUENCES OF EXPIRE AND TERMINATION
         --------------------------------------

         7.1      On expiry or termination of this Agreement for any reason:

                                      -13-
<PAGE>
                                              [CONFIDENTIAL TREATMENT REQUESTED]

                  7.1.1    Subject to Clause 7.1.2, each party shall return all
         materials containing any Background Information in its possession or
         control to the party which made such Background Information available;
         and

                  7.1.2    Subject to Clause 7.2, the provisions of Clauses 1,
         4.2, 4.4 to 4.7 inclusive, 5, 7 and 8 shall continue in full force and
         effect.

         7.2      Within 30 days of the date of expiry or termination of this
Agreement, ACD shall notify Somantis with a final project report setting out a
full description of the methods used to carry out the Research Project, the raw
results arising out of the Research Project, analysis of the raw results of the
Research Project and a description of any inventions made in the course of
carrying out the Research Project.

         7.3      Expiry and termination of this Agreement shall be without
prejudice to any other right or remedy for breach of this Agreement which either
party may have which accrued on or prior to the date of expiry or termination
(including, without limitation. Somantis' rights to receive the payments
specified in Clause 3).

         7.4      In the event that Somantis discontinues pursuing the
technology licensed to ACD under this Agreement, Somantis agrees to continue to
support ACD under the terms and conditions of this Agreement.

8.       GENERAL
         -------

         8.1      Notices
                  -------

                  8.1.1    Any notice or other communication given under this
         Agreement shall be in writing and shall be sent by pre-paid first class
         mail or by fax (confirmed by pre-paid first class mail placed in the
         post on or on the day after the date of transmission) to the other

                                      -14-
<PAGE>
                                              [CONFIDENTIAL TREATMENT REQUESTED]

         party at the address set out at the beginning of this Agreement or to
         such other address or fax number as may from time to time be notified
         to the other party in writing.

                  8.1.2    Any notice so sent by pre-paid first class mail shall
         be deemed to have been given on the third business day from and
         including the date of posting. Any notice so sent by fax (and confirmed
         by first class mail as aforesaid) shall be deemed to have been given
         the next business day following the day of transmission.

         8.2      Severability
                  ------------

         If any provision of this Agreement is declared by any judicial or other
competent authority to be void, voidable, illegal or otherwise unenforceable
then the remaining provisions of this Agreement shall continue in full force and
effect. The judicial or other competent authority making such determination
shall have the power to limit, construe or reduce the duration, scope, activity
and/or area of such provision, and/or delete specific words or phrases as
necessary to render, such provision enforceable.

         8.3      Waiver
                  ------

         Failure or delay by any party to exercise any right or remedy under
this Agreement shall not be deemed to be a waiver of that right or remedy, or
prevent it from exercising that or any other right or remedy on that occasion or
on any other occasion.

         8.4      Entire Agreement and Amendments
                  -------------------------------

                  8.4.1    This Agreement constitutes the entire agreement and
         understanding of the parties relating to the subject matter of this
         Agreement and supersedes all prior oral or written agreements,
         representations, understandings or arrangements between the parties.

                                      -15-
<PAGE>
                                              [CONFIDENTIAL TREATMENT REQUESTED]

                  8.4.2    The parties acknowledge that they are not relying on
         any agreement, understanding, arrangement, warranty, representation or
         term which is not set out in this Agreement.

                  8.4.3    Nothing in this Clause 8.4 shall operate to:

                  8.4.3.1  exclude any provision implied into this Agreement by
         law and which may not be excluded by law; or

                  8.4.3.2  limit or exclude any liability, right or remedy to a
         greater extent than is permissible under law.

                  8.4.4    No change may be made to this Agreement except in
         writing signed by the duly authorized representatives of each of the
         parties.

         8.5      Relationship of the Parties
                  ---------------------------

                  8.5.1    Nothing in this Agreement shall create evidence or
         imply any agency, partnership or joint venture between the parties.

                  8.5.2    No party shall act or describe itself as the agent of
         any of the other parties nor shall a party represent that it has any
         authority to make commitments on behalf of the other parties.

         8.6      Assignment and Sub-contracting
                  ------------------------------

         This Agreement is personal to the parties and neither party shall
assign, transfer, charge, or otherwise deal in its rights or obligations under
this Agreement except as expressly provided in this Agreement; provided,
however, that either party may assign this agreement without consent in
connection with a sale or other transfer or change in control of all or
substantially all of the assets of such party to which this Agreement relates.
This Agreement will be binding on successors and assigns.

                                      -16-
<PAGE>
                                              [CONFIDENTIAL TREATMENT REQUESTED]

         8.7      Publicity
                  ---------

         Except as required by law or regulation, no shall make any
announcement, or comment upon, or originate any publicity, or otherwise provide
any information to any third party (other than its legal advisors) concerning
this Agreement (including without limitation the existence of this Agreement,
the performance of this Agreement and/or any dispute, arbitration or
disagreement relating to this Agreement) without the prior written consent of
the other parties.

         8.8      Further Assurances
                  ------------------

         As and when requested by another party, each party shall, and shall
procure that their respective employees shall, do all acts and execute all
documents as may be reasonably necessary to give effect to the provisions of
this Agreement.

         8.9      Headings
                  --------

         The headings used in this Agreement are for convenience only and shall
not affect the interpretation of this Agreement.

         8.10     Law and Jurisdiction
                  --------------------

         The validity, construction and performance of this Agreement shall be
governed by the laws of New York, and the parties accept the exclusive
jurisdiction of the Courts in New York in respect thereof. Both parties will
abide by standard arbitration prior to any legal procedures.

                                      -17-
<PAGE>
                                              [CONFIDENTIAL TREATMENT REQUESTED]

For and on behalf of                       For and on behalf of
ACD                                        SOMANTIS LIMITED

/s/ BALBIR S. BRAR                         /s/ AGAMEMNON A. EPENETOS
------------------------------------       ------------------------------------
Signed                                     signed

Balbir S. Brar                             Agamemnon A. Epenetos
------------------------------------       ------------------------------------
print name                                 print name

illegible                                  Chairman and CEO
------------------------------------       ------------------------------------
title                                      title

31/8/04                                    31/8/04
------------------------------------       ------------------------------------
date                                       date

                      ACD Research PROJECT PLAN SCHEDULE I

[CONFIDENTIAL TREATMENT REQUESTED]

                                      -18-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}]]